February 24, 2022

Expanded Eligibility for COVID-19 Pre-exposure Prophylaxis for Patients with Moderate/Severe Immunocompromise

This health alert provides updates on patient eligibility for EVUSHELD, a long-acting monoclonal antibody that is available under U.S. Food and Drug Administration Emergency Use Authorization for pre-exposure prophylaxis to prevent COVID-19 infection in persons with moderate to severe immunocompromise. Additional groups of people in Maine are now eligible to get pre-exposure prophylaxis. For the latest information regarding the patient conditions that determine eligibility for EVUSHELD and the locations in Maine where this medication is available, visit the Maine CDC COVID-19: Healthcare Providers page at https://www.maine.gov/dhhs/mecdc/infectious-disease/epi/airborne/coronavirus/providers.shtml#prophylaxis

Advisory (PDF)